Literatur
- 1
Appel G B, Contreras G, Dooley M A. et al., Management Study Group .
Mycophenolate mofetil versus cyclophosphamide for induction
treatment of lupus nephritis.
J Am Soc Nephrol.
2009;
20
1103-1112
- 2
Dachverband Osteologie e. V .
DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der
Osteoporose bei Erwachsenen.
Osteologie.
2009;
18
304-328
- 3
Ginzler E M, Wofsy D, Isenberg D. et al., ALMS Group .
Nonrenal disease activity
following mycophenolate mofetil or intravenous cyclophosphamide
as induction treatment for lupus nephritis: findings in a multicenter,
prospective, randomized, open-label, parallel-group clinical trial.
Arthritis Rheum.
2010;
62
211-221
- 4
Kremer J M, Bloom B J, Breedveld F C. et al .
The safety and efficacy
of a JAK inhibitor in patients with active rheumatoid arthritis
results of a double-blind, placebo-controlled phase IIa trial of
three dosage levels of CP-690,550 versus placebo.
Arthritis Rheum.
2009;
60
1895-1905
- 5
Quartuccio L, Fabris M, Salvin S. et al .
Rheumatoid factor positivity rather than
anti-CCP positivity, a lower disability and a lower number of anti-TNF
agents failed are associated with response to rituximab in rheumatoid
arthritis.
Rheumatology.
2009;
48
1557-1559
- 6
Wallace D J, Stohl W, Furie R A. et al .
A phase II, randomized, double-blind, placebo-controlled,
dose-ranging study of belimumab in patients with active systemic
lupus erythematosus.
Arthritis Rheum.
2009;
61
1168-1178
- 7
Wollenhaupt J, Alten R, Backhaus M. et al .
Aktualisiertes Therapieschema der Rheumatoiden
Arthritis. Ergebnisse eines Konsensusprozesses deutscher Rheumatologen
2009.
Akt Rheumatol.
2009;
34
234-239
Prof. Dr. med. Ulf Müller-Ladner
Lehrstuhl für Innere Medizin mit Schwerpunkt
Rheumatologie der Justus-Liebig Universität Giessen, Abteilung
für Rheumatologie und klinische Immunologie Kerckhoff-Klinik
Bad Nauheim
Benekestrasse 2–8
61231
Bad Nauheim
Phone: 06032/9962101
Fax: 06032/9962104
Email: u.mueller-ladner@kerckhoff-klinik.de
